Virica Biotech - About the company
Virica Biotech is a series A company based in Ottawa (Canada), founded in 2018 by Jean Simon Diallo. It operates as a Developer of viral sensitizer technology therapeutics to treat viral infections. Virica Biotech has raised $11.6M in funding from Dynamk Capital. The company has 360 active competitors, including 107 funded and 79 that have exited. Its top competitors include companies like HOOKIPA Pharma, Regenxbio and Atea.
Company Details
Developer of viral sensitizer technology therapeutics to treat viral infections. The novel Viral Sensitizer technology consists of a library of small molecules (novel Viral Sensitizers) identified using a high-throughput screening process to target viral infections.
- Website
- www.viricabiotech.com/
- Email ID
- *****@viricabiotech.com
Key Metrics
Founded Year
2018
Location
Ottawa, Canada
Stage
Series A
Total Funding
$11.6M in 6 rounds
Latest Funding Round
Investors
Ranked
23rd among 360 active competitors
Employee Count
35 as on Sep 30, 2026
Similar Companies
Legal entities associated with Virica Biotech
Virica Biotech is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Virica Biotech Inc. CIN: 1892496 , United States, Active | $1 - $1M (As on Jun 16, 2022) | - | - |
Sign up to download Virica Biotech's company profile
Virica Biotech's funding and investors
Virica Biotech has raised a total funding of $11.6M over 6 rounds. Its first funding round was on Oct 04, 2021. Virica Biotech has 6 institutional investors.
Here is the list of recent funding rounds of Virica Biotech:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 29, 2024 | 2366753 | Series A | 7966505 | 6946928 | 8367129 | 8914680 |
Jan 22, 2024 | 7611986 | Series A | 1572941 | 4713826 | 2951090 | 9302635 |
Apr 21, 2023 | 9667590 | Grant (prize money) | 3872755 | 8559541 | 3303825 |
Access funding benchmarks and valuations. Sign up today!View details of Virica Biotech's funding rounds and investors
Virica Biotech's founders and board of directors
Founder? Claim ProfileThe founders of Virica Biotech is Jean Simon Diallo. Jean Simon Diallo is the CEO of Virica Biotech.
Here are the details of Virica Biotech's key team members:
- Jean Simon Diallo: Founder & CEO of Virica Biotech.
View details of Virica Biotech's Founder profiles and Board Members
Virica Biotech's employee count trend
Virica Biotech has 35 employees as of Sep 26. Here is Virica Biotech's employee count trend over the years:
Uncover Virica Biotech's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Virica Biotech's Competitors and alternates
Top competitors of Virica Biotech include HOOKIPA Pharma, Regenxbio and Atea. Here is the list of Top 10 competitors of Virica Biotech, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  HOOKIPA Pharma 2011, Vienna (Austria), Public | Developer of immunotherapies for the treatment of infectious diseases and cancer | $134M | 70/100 | |
2nd | Regenxbio 2008, Rockville (United States), Public | Developer of AAV Gene Therapy for rare genetic diseases | $108M | 67/100 | |
3rd | _1579497693661.png?devicePixelRatio=2&height=30&width=30){kind=logo} Atea 2014, Boston (United States), Public | Developer of therapeutics for viral diseases | $293M | 67/100 | |
4th | Vaxart 2004, San Francisco (United States), Public | Developer of therapeutic solutions for treating multiple infectious diseases | $58M | 67/100 | |
5th | Tonix Pharma 2007, New York City (United States), Public | Developer of next-generation medicines for CNS and immunological disorders | $4.45M | 66/100 | |
6th |  Brii Biosciences 2018, San Francisco (United States), Public | Developer of biologics to treat hepatitis B infection | $415M | 63/100 | |
7th |  Leyden Labs 2020, Leiden (Netherlands), Series B | Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa | $303M | 63/100 | |
8th | _1551769784760.png?devicePixelRatio=2&height=30&width=30){kind=logo} Rejuvenate Bio 2018, San Diego (United States), Series A | Developer of gene therapies for treating chronic and age-related diseases | $34M | 63/100 | |
9th |  Ascletis Pharma 2011, Hangzhou (China), Public | Developer of small molecules for the treatment of multiple diseases | $255M | 62/100 | |
10th |  eradivir 2020, West Lafayette (United States), Series A | Developer of immunotherapies for the treatment of infectious diseases | $20.4M | 62/100 | |
23rd |  Virica Biotech 2018, Ottawa (Canada), Series A | Developer of viral sensitizer technology therapeutics to treat viral infections | $11.6M | 57/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Virica Biotech's competitors? Click here to see the top ones
Virica Biotech's Investments and acquisitions
Virica Biotech has made no investments or acquisitions yet.
Reports related to Virica Biotech
Here is the latest report on Virica Biotech's sector:
News related to Virica Biotech
Filter this listMedia has covered Virica Biotech for 1 event in last 1 year, It was about partnerships.
•
Virica Biotech and FUJIFILM Biosciences collaborate under the Canada-Japan Co-Innovation Program to advance AAV production enhancersBusiness Wire•Apr 08, 2026•Virica Biotech, Fujifilm
•
Culture Biosciences Opens INTERPHEX 2025 with Launch of Cloud-Integrated Mobile BioreactorPharmtech•Apr 02, 2025•Culture Biosciences, Virica Biotech
•
•
eXmoor, Virica Partner to Enhance AAV ProductionContract Pharma•Oct 18, 2024•eXmoor, Virica Biotech, Government of Canada
•
eXmoor and Virica receive funding to improve AAV gene therapy manufacturingBusiness Wire•Oct 17, 2024•eXmoor, Virica Biotech
•
Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy ManufacturingFinancial Post•Oct 03, 2024•Virica Biotech
•
Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy ManufacturingBusiness Wire•Oct 03, 2024•Virica Biotech
•
Virica Biotech to double workforce as biosciences trailblazerOttawa Business Journal•Jun 29, 2024•Virica Biotech
•
Virica Expands Bioprocessing Capabilities with Carleton University PartnershipBusiness Wire•Jan 17, 2024•Virica Biotech, Carleton
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Virica Biotech
Explore our recently published companies
- Nic Beddoe Insurance - Truckee based, Unfunded company
- Jerry Tench Insurance - San Francisco based, Unfunded company
- Cesar Carrillo Insurance - Island Lake based, Unfunded company
- Clinton Raines - Atlanta based, Unfunded company
- Brian Himmelman State Farm - Conifer based, Unfunded company
- Curt Sumpter State Farm - Silver Spring based, Unfunded company
